Per Hellsund was Appointed as Chief Executive Officer at Cybrexa-Therapeutics

Date of management change: January 14, 2017 

What Happened?

New Haven, CT-based Cybrexa-Therapeutics Appointed Per Hellsund as Chief Executive Officer

 

About the Company

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.

 

About the Person

Per Hellsund is Chief Executive Officer at Cybrexa Therapeutics. Previously, Per  held various senior HR leadership roles in the industry.

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Gilliland Amy, Stevens Jason, Wilensky Stuart, David Carrie, Clark Larry, Sabo Susan, Kelly Maxine, Hua Olivier, Chiba Kimiaki, Loving Brenda, vanDyck John

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.